Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049)

医学 内科学 临床终点 肺癌 多西紫杉醇 化疗 无进展生存期 临床研究阶段 放射治疗 前瞻性队列研究 肿瘤科 阶段(地层学) 危险系数 置信区间 临床试验 古生物学 生物
作者
Rui Zhou,Bo Qiu,Mai Xiong,Yimei Liu,Kangqiang Peng,Yifeng Luo,Daquan Wang,FangJie Liu,NaiBin Chen,JinYu Guo,Jun Zhang,Xiaoyan Huang,YuMing Rong,Hui Liu
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:117 (2): 387-399 被引量:17
标识
DOI:10.1016/j.ijrobp.2023.04.021
摘要

We launched a prospective phase 2 clinical trial to explore the safety and efficacy of hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC).Patients with newly diagnosed LA-NSCLC with unresectable stage III disease were recruited between June 2018 and June 2020. Patients were treated with hypo-RT (40 Gy in 10 fractions) followed by hypo-boost (24-28 Gy in 6-7 fractions) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2 and nedaplatin 25 mg/m2). The primary endpoint of the study was progression-free survival (PFS), and the secondary endpoints included overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), objective response rate (ORR), and toxicities.From June 2018 to June 2020, 75 patients were enrolled with a median follow-up duration of 28.0 months. The ORR of the whole cohort was 94.7%. Disease progression or death was recorded in 44 (58.7%) patients, with a median PFS of 21.6 months (95% confidence interval [CI], 15.6-27.6 months). The 1- and 2-year PFS rates were 81.3% (95% CI, 72.5%-90.1%) and 43.3% (95% CI, 31.5%-55.1%), respectively. The median OS, DMFS, and LRFS had not been reached at the time of the last follow-up. The 1- and 2-year OS rates were 94.7% (95% CI, 89.6%-99.8%) and 72.4% (95% CI, 62.0%-82.8%), respectively. The most frequent acute nonhematologic toxicity was radiation esophagitis. Grade (G) 2 and G3 acute radiation esophagitis were observed in 20 (26.7%) and 4 (5.3%) patients, respectively. Thirteen patients (13/75, 17.3%) had G2 pneumonitis and no G3-G5 acute pneumonitis occurred during follow-up.Hypo-RT followed by hypo-boost combined with concurrent weekly chemotherapy could yield satisfactory local control and survival outcomes with moderate radiation-induced toxicity in patients with LA-NSCLC. The new potent hypo-CCRT regimen significantly shortened treatment time and provided the potential opportunity for the combination of consolidative immunotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
归尘发布了新的文献求助10
1秒前
卿卿完成签到,获得积分20
1秒前
2秒前
小毛球发布了新的文献求助10
2秒前
ket的应助被冬天了没采纳,获得10
2秒前
LU完成签到 ,获得积分10
3秒前
强强发布了新的文献求助10
4秒前
zhuang完成签到,获得积分10
4秒前
4秒前
研友_VZG7GZ的应助被cleva采纳,获得10
5秒前
5秒前
5秒前
5秒前
墨白发布了新的文献求助10
6秒前
wwwwyg完成签到,获得积分20
6秒前
我是谁的应助被青菜采纳,获得30
6秒前
QINFEIYAN完成签到 ,获得积分10
6秒前
orixero的应助被耶耶业采纳,获得10
6秒前
科研通AI65的应助被YM采纳,获得10
7秒前
7秒前
好的呢发布了新的文献求助10
7秒前
朴实剑通完成签到,获得积分10
8秒前
8秒前
你我山巅自相逢完成签到 ,获得积分10
9秒前
xiaoxiao完成签到,获得积分10
9秒前
瘦瘦的百褶裙完成签到 ,获得积分10
9秒前
9秒前
天极焉加完成签到,获得积分10
9秒前
10秒前
10秒前
李仟亿完成签到,获得积分10
10秒前
浩多多完成签到,获得积分10
10秒前
放松完成签到 ,获得积分10
11秒前
12秒前
12秒前
慕青的应助被周一采纳,获得10
13秒前
even完成签到,获得积分10
13秒前
科研通AI6.4的应助被WHW采纳,获得10
14秒前
地球完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128